| Chronic Obstructive Airway Disease
Breyna vs Incruse Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Breyna vs Incruse Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIncruse Ellipta has a higher rate of injection site reactions vs Breyna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Incruse Ellipta but not Breyna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breyna
Incruse Ellipta
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
Long-acting muscarinic antagonist
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
Dosing
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation; use at the same time every day; do not use more than 1 time every 24 hours. No dosage adjustment required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
- Severe hypersensitivity to milk proteins
- Hypersensitivity to umeclidinium or any of the excipients
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, cough, arthralgia, pharyngitis, viral upper respiratory tract infection, myalgia, abdominal pain upper, toothache, contusion, tachycardia
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Eye pain, glaucoma, vision blurred, anaphylaxis, angioedema, pruritus, urticaria, dysuria, urinary retention, dysphonia, oropharyngeal pain
Pharmacology
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Long-acting muscarinic antagonist (LAMA/anticholinergic); competitively and reversibly inhibits M3 receptors at airway smooth muscle to produce bronchodilation lasting longer than 24 hours after once-daily oral inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
Incruse Ellipta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Incruse Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Incruse Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breyna.
No savings programs available for Incruse Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreynaView full Breyna profile
Incruse ElliptaView full Incruse Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.